Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:UBR5-DRD4

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: UBR5-DRD4
	FusionPDB ID: 96465
	FusionGDB2.0 ID: 96465
		Hgene	Tgene
	Gene symbol	UBR5	DRD4
	Gene ID	51366	1815
	Gene name	ubiquitin protein ligase E3 component n-recognin 5	dopamine receptor D4
	Synonyms	DD5\|EDD\|EDD1\|HYD	D4DR
	Cytomap	8q22.3	11p15.5
	Type of gene	protein-coding	protein-coding
	Description	E3 ubiquitin-protein ligase UBR5E3 identified by differential displayE3 ubiquitin-protein ligase, HECT domain-containing 1HECT-type E3 ubiquitin transferase UBR5hyperplastic discs protein homologprogestin-induced protein	D(4) dopamine receptorD(2C) dopamine receptordopamine D4 receptorseven transmembrane helix receptor
	Modification date	20200315	20200329
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000220959, ENST00000520539, ENST00000521922, ENST00000518205, ENST00000519528,	ENST00000528733, ENST00000176183,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	21 X 15 X 11=3465	4 X 5 X 3=60
	# samples	25	7
	** MAII score	log2(25/3465*10)=-3.79285535236249 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(7/60*10)=0.222392421336448 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0
Fusion gene context	PubMed: UBR5 [Title/Abstract] AND DRD4 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: UBR5 [Title/Abstract] AND DRD4 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	UBR5(103424400)-DRD4(639432), # samples:1 UBR5(103424401)-DRD4(639433), # samples:1 UBR5(103424401)-DRD4(640401), # samples:1
Anticipated loss of major functional domain due to fusion event.	UBR5-DRD4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. UBR5-DRD4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. UBR5-DRD4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. UBR5-DRD4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. UBR5-DRD4 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. UBR5-DRD4 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF. UBR5-DRD4 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. UBR5-DRD4 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	UBR5	GO:0000209	protein polyubiquitination	21118991\|28689657
Hgene	UBR5	GO:0006974	cellular response to DNA damage stimulus	12011095
Hgene	UBR5	GO:0010628	positive regulation of gene expression	18076571
Hgene	UBR5	GO:0050847	progesterone receptor signaling pathway	12011095
Hgene	UBR5	GO:0070936	protein K48-linked ubiquitination	28689657
Tgene	DRD4	GO:0000187	activation of MAPK activity	9843378\|15755724
Tgene	DRD4	GO:0007195	adenylate cyclase-inhibiting dopamine receptor signaling pathway	7512953\|9003072\|9843378
Tgene	DRD4	GO:0007212	dopamine receptor signaling pathway	1840645
Tgene	DRD4	GO:0032417	positive regulation of sodium:proton antiporter activity	7512953
Tgene	DRD4	GO:0033674	positive regulation of kinase activity	15755724
Tgene	DRD4	GO:0034776	response to histamine	16839358
Tgene	DRD4	GO:0050482	arachidonic acid secretion	7512953
Tgene	DRD4	GO:0050709	negative regulation of protein secretion	16839358
Tgene	DRD4	GO:1901386	negative regulation of voltage-gated calcium channel activity	7921596

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:103424400/chr11:639432)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across UBR5 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across DRD4 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000520539	UBR5	chr8	103424400	-	ENST00000176183	DRD4	chr11	639432	+	1747	669	662	1729	355
ENST00000220959	UBR5	chr8	103424400	-	ENST00000176183	DRD4	chr11	639432	+	1595	517	510	1577	355
ENST00000521922	UBR5	chr8	103424400	-	ENST00000176183	DRD4	chr11	639432	+	1665	587	580	1647	355
ENST00000520539	UBR5	chr8	103424401	-	ENST00000176183	DRD4	chr11	639433	+	1747	669	662	1729	355
ENST00000220959	UBR5	chr8	103424401	-	ENST00000176183	DRD4	chr11	639433	+	1595	517	510	1577	355
ENST00000521922	UBR5	chr8	103424401	-	ENST00000176183	DRD4	chr11	639433	+	1665	587	580	1647	355

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000520539	ENST00000176183	UBR5	chr8	103424400	-	DRD4	chr11	639432	+	0.583429	0.41657102
ENST00000220959	ENST00000176183	UBR5	chr8	103424400	-	DRD4	chr11	639432	+	0.6738702	0.3261298
ENST00000521922	ENST00000176183	UBR5	chr8	103424400	-	DRD4	chr11	639432	+	0.67526627	0.3247337
ENST00000520539	ENST00000176183	UBR5	chr8	103424401	-	DRD4	chr11	639433	+	0.583429	0.41657102
ENST00000220959	ENST00000176183	UBR5	chr8	103424401	-	DRD4	chr11	639433	+	0.6738702	0.3261298
ENST00000521922	ENST00000176183	UBR5	chr8	103424401	-	DRD4	chr11	639433	+	0.67526627	0.3247337

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for UBR5-DRD4

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
UBR5	chr8	103424400	DRD4	chr11	639432	517	108	GPRLRGLLVRVLLLPTLPAHAAALLG
UBR5	chr8	103424400	DRD4	chr11	639432	517	139	AALGGGTSRQAARPRAPPTQRPWPAF
UBR5	chr8	103424400	DRD4	chr11	639432	517	156	PTQRPWPAFPHATRAPPPPGPLRPRL
UBR5	chr8	103424400	DRD4	chr11	639432	517	37	AVHRLHLQPVRHQRGQVRGRGRAAAL
UBR5	chr8	103424400	DRD4	chr11	639432	517	40	RLHLQPVRHQRGQVRGRGRAAALQPA
UBR5	chr8	103424400	DRD4	chr11	639432	517	65	AGWEPPAAAAHRRHVAAVRGGGGART
UBR5	chr8	103424400	DRD4	chr11	639432	587	108	GPRLRGLLVRVLLLPTLPAHAAALLG
UBR5	chr8	103424400	DRD4	chr11	639432	587	139	AALGGGTSRQAARPRAPPTQRPWPAF
UBR5	chr8	103424400	DRD4	chr11	639432	587	156	PTQRPWPAFPHATRAPPPPGPLRPRL
UBR5	chr8	103424400	DRD4	chr11	639432	587	37	AVHRLHLQPVRHQRGQVRGRGRAAAL
UBR5	chr8	103424400	DRD4	chr11	639432	587	40	RLHLQPVRHQRGQVRGRGRAAALQPA
UBR5	chr8	103424400	DRD4	chr11	639432	587	65	AGWEPPAAAAHRRHVAAVRGGGGART
UBR5	chr8	103424400	DRD4	chr11	639432	669	108	GPRLRGLLVRVLLLPTLPAHAAALLG
UBR5	chr8	103424400	DRD4	chr11	639432	669	139	AALGGGTSRQAARPRAPPTQRPWPAF
UBR5	chr8	103424400	DRD4	chr11	639432	669	156	PTQRPWPAFPHATRAPPPPGPLRPRL
UBR5	chr8	103424400	DRD4	chr11	639432	669	37	AVHRLHLQPVRHQRGQVRGRGRAAAL
UBR5	chr8	103424400	DRD4	chr11	639432	669	40	RLHLQPVRHQRGQVRGRGRAAALQPA
UBR5	chr8	103424400	DRD4	chr11	639432	669	65	AGWEPPAAAAHRRHVAAVRGGGGART
UBR5	chr8	103424401	DRD4	chr11	639433	517	108	GPRLRGLLVRVLLLPTLPAHAAALLG
UBR5	chr8	103424401	DRD4	chr11	639433	517	139	AALGGGTSRQAARPRAPPTQRPWPAF
UBR5	chr8	103424401	DRD4	chr11	639433	517	156	PTQRPWPAFPHATRAPPPPGPLRPRL
UBR5	chr8	103424401	DRD4	chr11	639433	517	37	AVHRLHLQPVRHQRGQVRGRGRAAAL
UBR5	chr8	103424401	DRD4	chr11	639433	517	40	RLHLQPVRHQRGQVRGRGRAAALQPA
UBR5	chr8	103424401	DRD4	chr11	639433	517	65	AGWEPPAAAAHRRHVAAVRGGGGART
UBR5	chr8	103424401	DRD4	chr11	639433	587	108	GPRLRGLLVRVLLLPTLPAHAAALLG
UBR5	chr8	103424401	DRD4	chr11	639433	587	139	AALGGGTSRQAARPRAPPTQRPWPAF
UBR5	chr8	103424401	DRD4	chr11	639433	587	156	PTQRPWPAFPHATRAPPPPGPLRPRL
UBR5	chr8	103424401	DRD4	chr11	639433	587	37	AVHRLHLQPVRHQRGQVRGRGRAAAL
UBR5	chr8	103424401	DRD4	chr11	639433	587	40	RLHLQPVRHQRGQVRGRGRAAALQPA
UBR5	chr8	103424401	DRD4	chr11	639433	587	65	AGWEPPAAAAHRRHVAAVRGGGGART
UBR5	chr8	103424401	DRD4	chr11	639433	669	108	GPRLRGLLVRVLLLPTLPAHAAALLG
UBR5	chr8	103424401	DRD4	chr11	639433	669	139	AALGGGTSRQAARPRAPPTQRPWPAF
UBR5	chr8	103424401	DRD4	chr11	639433	669	156	PTQRPWPAFPHATRAPPPPGPLRPRL
UBR5	chr8	103424401	DRD4	chr11	639433	669	37	AVHRLHLQPVRHQRGQVRGRGRAAAL
UBR5	chr8	103424401	DRD4	chr11	639433	669	40	RLHLQPVRHQRGQVRGRGRAAALQPA
UBR5	chr8	103424401	DRD4	chr11	639433	669	65	AGWEPPAAAAHRRHVAAVRGGGGART

Top

Potential FusionNeoAntigen Information of UBR5-DRD4 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

UBR5-DRD4_103424400_639432.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:05	VRVLLLPTL	0.9999	0.834	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:02	VRVLLLPTL	0.9999	0.5363	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:04	VRVLLLPTL	0.9999	0.826	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:07	VRVLLLPTL	0.9998	0.7377	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B39:24	VRVLLLPTL	0.9973	0.8435	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B14:02	VRVLLLPTL	0.9965	0.9721	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B14:01	VRVLLLPTL	0.9965	0.9721	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B39:06	VRVLLLPTL	0.9955	0.9592	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B39:01	VRVLLLPTL	0.9947	0.9508	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B38:01	VRVLLLPTL	0.9794	0.9888	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B38:02	VRVLLLPTL	0.9794	0.9903	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B08:01	GLLVRVLLL	0.96	0.5266	5	14
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-A02:13	GLLVRVLLL	0.9128	0.6067	5	14
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-A02:04	GLLVRVLLL	0.9097	0.5804	5	14
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-A02:38	GLLVRVLLL	0.8543	0.5375	5	14
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B15:10	VRVLLLPTL	0.8462	0.6621	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B15:37	VRVLLLPTL	0.7743	0.7612	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B07:10	VRVLLLPTL	0.0661	0.6384	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B55:01	LLPTLPAHAA	0.6967	0.7624	12	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B56:01	LLPTLPAHAA	0.5985	0.8887	12	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B56:01	LLLPTLPAHAA	0.7925	0.8729	11	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B55:01	LLLPTLPAHAA	0.7042	0.7369	11	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:14	VRVLLLPTL	0.9999	0.8228	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:95	VRVLLLPTL	0.9987	0.7786	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:05	VRVLLLPTL	0.9984	0.9613	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:27	VRVLLLPTL	0.9975	0.9651	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B39:09	VRVLLLPTL	0.9962	0.9224	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:29	VRVLLLPTL	0.9959	0.9575	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B39:12	VRVLLLPTL	0.9943	0.9565	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:03	VRVLLLPTL	0.994	0.8598	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:13	VRVLLLPTL	0.9938	0.9671	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B73:01	VRVLLLPTL	0.9863	0.9403	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:46	VRVLLLPTL	0.9721	0.9532	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-A02:07	LLPTLPAHA	0.9487	0.792	12	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:80	VRVLLLPTL	0.9262	0.9744	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:67	VRVLLLPTL	0.9262	0.9744	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:19	VRVLLLPTL	0.9234	0.9011	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:10	VRVLLLPTL	0.9166	0.9788	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B15:04	LLLPTLPAH	0.6901	0.9831	11	20
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B14:03	VRVLLLPTL	0.6357	0.951	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C12:16	VRVLLLPTL	0.1376	0.9841	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B54:01	LLPTLPAHAA	0.9182	0.9766	12	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B54:01	LLLPTLPAHAA	0.9446	0.9785	11	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:08	VRVLLLPTL	0.9999	0.7433	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:06	VRVLLLPTL	0.9999	0.8164	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:10	VRVLLLPTL	0.9999	0.8979	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B27:09	VRVLLLPTL	0.9998	0.8294	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:01	VRVLLLPTL	0.9989	0.7812	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B39:31	VRVLLLPTL	0.9939	0.9532	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:17	VRVLLLPTL	0.9867	0.979	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C06:08	VRVLLLPTL	0.9829	0.9926	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B38:05	VRVLLLPTL	0.9794	0.9888	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B08:18	GLLVRVLLL	0.96	0.5266	5	14
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:02	VRVLLLPTL	0.9262	0.9744	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C07:22	VRVLLLPTL	0.905	0.7918	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C06:17	VRVLLLPTL	0.2918	0.9952	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-C06:02	VRVLLLPTL	0.2918	0.9952	8	17
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B55:02	LLPTLPAHAA	0.6159	0.9477	12	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B56:05	LLPTLPAHAA	0.5085	0.9214	12	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	HLA-B55:02	LLLPTLPAHAA	0.7345	0.9549	11	22

Top

Potential FusionNeoAntigen Information of UBR5-DRD4 in HLA II

UBR5-DRD4_103424400_639432.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0413	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0413	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0415	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0415	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0415	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0427	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0427	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0436	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0436	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0436	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0437	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0440	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0440	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0442	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0442	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0444	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0444	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0444	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0451	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0453	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0453	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0453	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0455	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0456	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0456	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0458	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0458	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0458	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0459	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0468	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0468	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0470	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0470	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0473	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0478	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0479	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0479	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0479	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-0488	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1002	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1204	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1204	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1204	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1209	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1209	LLVRVLLLPTLPAHA	6	21
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1209	VRVLLLPTLPAHAAA	8	23
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1452	LVRVLLLPTLPAHAA	7	22
UBR5-DRD4	chr8	103424400	chr11	639432	517	DRB1-1452	LLVRVLLLPTLPAHA	6	21

Top

Fusion breakpoint peptide structures of UBR5-DRD4

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5285	LLVRVLLLPTLPAH	UBR5	DRD4	chr8	103424400	chr11	639432	517

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of UBR5-DRD4

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	5285	LLVRVLLLPTLPAH	-7.9962	-8.1096
HLA-B14:02	3BVN	5285	LLVRVLLLPTLPAH	-5.70842	-6.74372
HLA-B52:01	3W39	5285	LLVRVLLLPTLPAH	-6.83737	-6.95077
HLA-B52:01	3W39	5285	LLVRVLLLPTLPAH	-4.4836	-5.5189
HLA-A11:01	4UQ2	5285	LLVRVLLLPTLPAH	-10.0067	-10.1201
HLA-A11:01	4UQ2	5285	LLVRVLLLPTLPAH	-9.03915	-10.0745
HLA-A24:02	5HGA	5285	LLVRVLLLPTLPAH	-6.56204	-6.67544
HLA-A24:02	5HGA	5285	LLVRVLLLPTLPAH	-5.42271	-6.45801
HLA-B44:05	3DX8	5285	LLVRVLLLPTLPAH	-7.85648	-8.89178
HLA-B44:05	3DX8	5285	LLVRVLLLPTLPAH	-5.3978	-5.5112
HLA-A02:01	6TDR	5285	LLVRVLLLPTLPAH	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of UBR5-DRD4

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
UBR5-DRD4	chr8	103424400	chr11	639432	11	20	LLLPTLPAH	TGACAGGTCCAGGGTGGCGCGTGGCTG
UBR5-DRD4	chr8	103424400	chr11	639432	11	22	LLLPTLPAHAA	TGACAGGTCCAGGGTGGCGCGTGGCTGCTGAGC
UBR5-DRD4	chr8	103424400	chr11	639432	12	21	LLPTLPAHA	CAGGTCCAGGGTGGCGCGTGGCTGCTG
UBR5-DRD4	chr8	103424400	chr11	639432	12	22	LLPTLPAHAA	CAGGTCCAGGGTGGCGCGTGGCTGCTGAGC
UBR5-DRD4	chr8	103424400	chr11	639432	5	14	GLLVRVLLL	CACCGAGGACCAGCTCAATGACAGGTC
UBR5-DRD4	chr8	103424400	chr11	639432	8	17	VRVLLLPTL	CCAGCTCAATGACAGGTCCAGGGTGGC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
UBR5-DRD4	chr8	103424400	chr11	639432	6	21	LLVRVLLLPTLPAHA	CGAGGACCAGCTCAATGACAGGTCCAGGGTGGCGCGTGGCTGCTG
UBR5-DRD4	chr8	103424400	chr11	639432	7	22	LVRVLLLPTLPAHAA	GGACCAGCTCAATGACAGGTCCAGGGTGGCGCGTGGCTGCTGAGC
UBR5-DRD4	chr8	103424400	chr11	639432	8	23	VRVLLLPTLPAHAAA	CCAGCTCAATGACAGGTCCAGGGTGGCGCGTGGCTGCTGAGCCCC

Top

Information of the samples that have these potential fusion neoantigens of UBR5-DRD4

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
UCEC	UBR5-DRD4	chr8	103424400	ENST00000220959	chr11	639432	ENST00000176183	TCGA-BS-A0U9

Top

Potential target of CAR-T therapy development for UBR5-DRD4

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

DRD4

chr8:103424400

chr11:639432

ENST00000176183

111_131

420.0

Transmembrane

Helical%3B Name%3D3

Tgene

DRD4

chr8:103424400

chr11:639432

ENST00000176183

153_173

420.0

Transmembrane

Helical%3B Name%3D4

Tgene

DRD4

chr8:103424400

chr11:639432

ENST00000176183

193_213

420.0

Transmembrane

Helical%3B Name%3D5

Tgene

DRD4

chr8:103424400

chr11:639432

ENST00000176183

347_367

420.0

Transmembrane

Helical%3B Name%3D6

Tgene

DRD4

chr8:103424400

chr11:639432

ENST00000176183

383_403

420.0

Transmembrane

Helical%3B Name%3D7

Tgene

DRD4

chr8:103424401

chr11:639433

ENST00000176183

111_131

420.0

Transmembrane

Helical%3B Name%3D3

Tgene

DRD4

chr8:103424401

chr11:639433

ENST00000176183

153_173

420.0

Transmembrane

Helical%3B Name%3D4

Tgene

DRD4

chr8:103424401

chr11:639433

ENST00000176183

193_213

420.0

Transmembrane

Helical%3B Name%3D5

Tgene

DRD4

chr8:103424401

chr11:639433

ENST00000176183

347_367

420.0

Transmembrane

Helical%3B Name%3D6

Tgene

DRD4

chr8:103424401

chr11:639433

ENST00000176183

383_403

420.0

Transmembrane

Helical%3B Name%3D7

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to UBR5-DRD4

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to UBR5-DRD4

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)